2JQ Stock Overview
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Gritstone bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.68 |
52 Week High | US$2.68 |
52 Week Low | US$0.65 |
Beta | 0.43 |
1 Month Change | -73.56% |
3 Month Change | n/a |
1 Year Change | -71.38% |
3 Year Change | -91.08% |
5 Year Change | -94.67% |
Change since IPO | -93.50% |
Recent News & Updates
Recent updates
Shareholder Returns
2JQ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -13.8% | -5.1% | -2.0% |
1Y | -71.4% | -21.1% | -0.3% |
Return vs Industry: 2JQ underperformed the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 2JQ underperformed the German Market which returned -0.3% over the past year.
Price Volatility
2JQ volatility | |
---|---|
2JQ Average Weekly Movement | 31.2% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2JQ's share price has been volatile over the past 3 months.
Volatility Over Time: 2JQ's weekly volatility has increased from 21% to 31% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
2JQ fundamental statistics | |
---|---|
Market cap | €73.58m |
Earnings (TTM) | -€130.01m |
Revenue (TTM) | €15.34m |
4.9x
P/S Ratio-0.6x
P/E RatioIs 2JQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2JQ income statement (TTM) | |
---|---|
Revenue | US$16.34m |
Cost of Revenue | US$127.18m |
Gross Profit | -US$110.84m |
Other Expenses | US$27.65m |
Earnings | -US$138.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.30 |
Gross Margin | -678.16% |
Net Profit Margin | -847.34% |
Debt/Equity Ratio | 77.4% |
How did 2JQ perform over the long term?
See historical performance and comparison